- Home
- NCZ vs CADL Comparison
NCZ vs CADL Comparison
Compare NCZ & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCZ | CADL |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.5M | 339.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NCZ | CADL |
|---|---|---|
| Price | $14.11 | $6.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.43 |
| AVG Volume (30 Days) | 533.0K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 12.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $4.25 |
| 52 Week High | $3.15 | $13.68 |
Technical Indicators
Market Signals| Indicator | NCZ | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 58.65 | 62.01 |
| Support Level | $13.50 | $5.45 |
| Resistance Level | $13.91 | $6.14 |
| Average True Range (ATR) | 0.20 | 0.42 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 92.70 | 54.43 |
Price Performance
Historical ComparisonAbout NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.